Traws Pharma Inc
TRAW1.496USD
+0.036+2.47%
Market hours （ET）Quotes delayed by 15 min
7.59MMarket Cap
LossP/E TTM
More Details of Traws Pharma Inc Company
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Company Info
Ticker SymbolTRAW
Company nameTraws Pharma Inc
IPO dateJul 25, 2013
CEODr. Iain D. Dukes, Ph.D.
Number of employees7
Security typeOrdinary Share
Fiscal year-endJul 25
Address12 Penns Trail
CityNEWTOWN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code18940
Phone12677593680
Websitehttps://www.onconova.com/
Ticker SymbolTRAW
IPO dateJul 25, 2013
CEODr. Iain D. Dukes, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
+202.70%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Interim Chief Executive Officer, Company Secretary, Director
Interim Chief Executive Officer, Company Secretary, Director
81.19K
-2.44%
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
-11.11%
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. M. Teresa Shoemaker
Ms. M. Teresa Shoemaker
Independent Director
Independent Director
--
--
Dr. Werner Cautreels
Dr. Werner Cautreels
Director
Director
--
--
Dr. Trafford Clarke, Ph.D.
Dr. Trafford Clarke, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
+202.70%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Interim Chief Executive Officer, Company Secretary, Director
Interim Chief Executive Officer, Company Secretary, Director
81.19K
-2.44%
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
-11.11%
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Symbio
57.00K
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
57.00K
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Symbio
57.00K
0.00%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viriom Inc
10.88%
OrbiMed Advisors, LLC
10.88%
Perceptive Advisors LLC
7.58%
Adage Capital Management, L.P.
5.93%
Savchuk (Nikolay)
4.53%
Other
60.20%
Shareholders
Shareholders
Proportion
Viriom Inc
10.88%
OrbiMed Advisors, LLC
10.88%
Perceptive Advisors LLC
7.58%
Adage Capital Management, L.P.
5.93%
Savchuk (Nikolay)
4.53%
Other
60.20%
Shareholder Types
Shareholders
Proportion
Private Equity
18.46%
Corporation
10.88%
Individual Investor
7.84%
Hedge Fund
7.63%
Investment Advisor/Hedge Fund
4.58%
Investment Advisor
0.53%
Research Firm
0.02%
Other
50.05%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
57
2.78M
49.95%
+103.15K
2025Q1
59
3.22M
71.94%
+1.74M
2024Q4
58
1.47M
44.66%
+775.47K
2024Q3
57
942.34K
34.05%
+834.58K
2024Q2
58
213.81K
16.43%
+135.65K
2024Q1
55
74.05K
8.78%
-3.08K
2023Q4
60
70.75K
8.42%
-22.28K
2023Q3
70
76.41K
9.11%
-47.84K
2023Q2
73
78.91K
9.41%
-30.66K
2023Q1
104
61.55K
7.34%
-62.19K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viriom Inc
605.53K
10.88%
--
--
Apr 28, 2025
OrbiMed Advisors, LLC
605.53K
10.88%
--
--
Mar 31, 2025
Perceptive Advisors LLC
421.78K
7.58%
+257.62K
+156.94%
Mar 31, 2025
Adage Capital Management, L.P.
330.00K
5.93%
+330.00K
--
Mar 31, 2025
Savchuk (Nikolay)
251.90K
4.53%
+168.68K
+202.70%
Apr 28, 2025
Vestal Point Capital, LP
175.00K
3.15%
+100.00K
+133.33%
Mar 31, 2025
Cautreels (Werner C)
98.35K
1.77%
-6.00K
-5.75%
Apr 28, 2025
Dukes (Iain D)
81.19K
1.46%
-2.03K
-2.44%
Apr 28, 2025
Alyeska Investment Group, L.P.
52.63K
0.95%
-64.08K
-54.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
33.38K
0.6%
+12.58K
+60.47%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
Date
Type
Ratio
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
Sep 17, 2024
Merger
25<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
May 20, 2021
Merger
15<1
